N
Nuvation Bio Inc. (NUVB)
NYQ – Real vaqt narxi. Valyuta: USD
4.25
-0.17 (-3.85%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
4.22
-0.03 (-0.71%)
Bozordan keyin: Mar 27, 2026, 6:50 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NYQ – Real vaqt narxi. Valyuta: USD
4.25
-0.17 (-3.85%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
4.22
-0.03 (-0.71%)
Bozordan keyin: Mar 27, 2026, 6:50 PM EDT
Nuvation Bio Inc. klinik bosqichdagi biotexnologiya kompaniyasi bo'lib, saratonni davolash uchun mahsulot nomzodlarini ishlab chiqishga qaratilgan. Kompaniyaning asosiy mahsulot nomzodi IBTROZI (taletrectinib) bo'lib, u ROS1+ mayda hujayrali o'pka saratoni bilan og'rigan bemorlarni davolash uchun ROS1 ingibitoridir. Kompaniya, shuningdek, safusidenibni ishlab chiqmoqda, bu mutant izotsitrat dehidrogenaza 1 ning ingibitori bo'lib, u yuqori xavfli yoki yuqori darajadagi IDH1-mutant astrositomani safusidenibga qarshi platsebo bilan parvarishlash davolash uchun 3-bosqichli klinik sinovlarda. Kompaniya 2018-yilda tashkil etilgan va uning shtab-kvartirasi Nyu-York, Nyu-Yorkda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. David Liu M.D., Ph.D. | Chief Medical Officer |
| Dr. David C. Hanley Ph.D. | Chief Technical Operations Officer |
| Dr. David T. Hung M.D. | Founder, President, CEO & Chairman |
| Dr. Gary Hattersley Ph.D. | Chief Scientific Officer |
| Mr. Moses Makunje CPA | VP of Finance and Principal Accounting & Financial Officer |
| Mr. Philippe Pierre Sauvage | CFO & Principal Financial Officer |
| Ms. Colleen Sjogren | Chief Commercial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-03 | S-8 | d112224ds8.htm |
| 2026-03-02 | 8-K | d15383d8k.htm |
| 2026-01-12 | 8-K | d947742d8k.htm |
| 2025-11-26 | 8-K | d82457d8k.htm |
| 2025-11-17 | 8-K | d845081d8k.htm |
| 2025-11-03 | 10-Q | nuvb-20250930.htm |
| 2025-08-07 | 10-Q | nuvb-20250630.htm |
| 2025-06-11 | 8-K | d932856d8k.htm |
| 2025-05-23 | 8-K | d908097d8k.htm |
| 2025-05-07 | 10-Q | nuvb-20250331.htm |
| Ms. Kerry A. Wentworth |
| Chief Regulatory Officer |
| Ms. Stacy Markel | Chief People Officer |